Venous thrombembolism, thrombophilic defects, combined oral contraception and anticoagulation.

Background: Several genetic polymorphisms increase the risk for venous thrombembolism (VTE). In particular, combined oral contraceptives (COCs) are known to enhance the risk for VTE and are therefore contraindicated.

Case: We present here the case of a patient with protein S deficiency, who has used COCs together with anticoagulatory therapy (Phenprocoumon) after suffering from deep venous thromboses for 4 years. At the time of her first consultation at our clinic, the ultrasound examination showed a complete involution of her venous thrombosis.

Conclusion: COCs can be used in patients with thrombogenic mutations and anticoagulatory therapy in individual cases.